Clearmind, Yissum Apply for International Patent for Psychedelics

Dow Jones08-17

By Stephen Nakrosis

Clearmind Medicine said it applied for an international patent for its psychedelic compounds, as well as their preparation methods and use in the treatment of mental disorders.

The submission under the international Patent Cooperation Treaty is part of the company's collaboration with the Yissum Research Development Co. of Hebrew University of Jerusalem, with which Clearmind has a licensing agreement.

Clearmind, of Vancouver, British Columbia, said the application refers to what it calls Generation 3.0 psychedelic compounds developed by the Israeli university's Dmitry Tsvelikhovsky.

The biotechnology company also said the submission would allow it to proceed to the national phase and submit applications to regional offices for patent protection in major jurisdictions such as the U.S., Europe, China and India.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

August 16, 2024 17:15 ET (21:15 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2460221352?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-08-17 05:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2460221352","market":"us","top_or_hot":-1,"title":"Clearmind, Yissum Apply for International Patent for Psychedelics","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Stephen Nakrosis \n</p>\n<pre>\n \n</pre>\n<p>\n  Clearmind Medicine said it applied for an international patent for its psychedelic compounds, as well as their preparation methods and use in the treatment of mental disorders. \n</p>\n<p>\n  The submission under the international Patent Cooperation Treaty is part of the company's collaboration with the Yissum Research Development Co. of Hebrew University of Jerusalem, with which Clearmind has a licensing agreement. \n</p>\n<p>\n  Clearmind, of Vancouver, British Columbia, said the application refers to what it calls Generation 3.0 psychedelic compounds developed by the Israeli university's Dmitry Tsvelikhovsky. \n</p>\n<p>\n  The biotechnology company also said the submission would allow it to proceed to the national phase and submit applications to regional offices for patent protection in major jurisdictions such as the U.S., Europe, China and India. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 16, 2024 17:15 ET (21:15 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clearmind, Yissum Apply for International Patent for Psychedelics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClearmind, Yissum Apply for International Patent for Psychedelics\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-17 05:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Stephen Nakrosis \n\n\n \n\n\n  Clearmind Medicine said it applied for an international patent for its psychedelic compounds, as well as their preparation methods and use in the treatment of mental ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2460221352","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2460221352","pubTimestamp":1723842900,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Clearmind Medicine said it applied for an international patent for its psychedelic compounds, as well as their preparation methods and use in the treatment of mental disorders.The submission under the international Patent Cooperation Treaty is part of the company's collaboration with the Yissum Research Development Co. of Hebrew University of Jerusalem, with which Clearmind has a licensing agreement.Clearmind, of Vancouver, British Columbia, said the application refers to what it calls Generation 3.0 psychedelic compounds developed by the Israeli university's Dmitry Tsvelikhovsky.The biotechnology company also said the submission would allow it to proceed to the national phase and submit applications to regional offices for patent protection in major jurisdictions such as the U.S., Europe, China and India.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","CMND":"Clearmind Medicine, Inc."},"translate_title":"Clearmind、Yissum申请迷幻药国际专利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CMND":0.9},"content_text":"By Stephen Nakrosis \n\n\n \n\n\n  Clearmind Medicine said it applied for an international patent for its psychedelic compounds, as well as their preparation methods and use in the treatment of mental disorders. \n\n\n  The submission under the international Patent Cooperation Treaty is part of the company's collaboration with the Yissum Research Development Co. of Hebrew University of Jerusalem, with which Clearmind has a licensing agreement. \n\n\n  Clearmind, of Vancouver, British Columbia, said the application refers to what it calls Generation 3.0 psychedelic compounds developed by the Israeli university's Dmitry Tsvelikhovsky. \n\n\n  The biotechnology company also said the submission would allow it to proceed to the national phase and submit applications to regional offices for patent protection in major jurisdictions such as the U.S., Europe, China and India. \n\n\n \n\n\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 16, 2024 17:15 ET (21:15 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2460221352"}